S-ClassAbout S-Class
A
AZNAI Stock Diagnostic Report
AstraZeneca reiterates guidance after topping Q2 profit expectations; shares up
AstraZeneca's share price rose as it reaffirmed its annual guidance, buoyed by strong second‑quarter performance.
View Source Article ↗AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$169.26Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
Major SupportOMITTED
Near-Term ResistanceOMITTED
02
FUNDAMENTALS
Financial & Fundamental Analysis
Q2 results surpassed market expectations and reaffirmed annual guidance, confirming solid core business performance growth.
03
TECHNICAL VIEW
Technical Position & Response Criteria
RSI at 50.5 indicates a neutral state, and it is necessary to track the short-term rebound trend following improved performance.
SupportOMITTED
ResistanceOMITTED
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
Short-term momentum arising from earnings beat and reaffirmation of guidance.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-07-27)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.